World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
38795
World Ranking
6050
National Ranking
3236

Peter J. Houghton publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter J. Houghton sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 619 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter J. Houghton D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter J. Houghton sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Peter J. Houghton is affiliated with The University of Texas Health Science Center at San Antonio in the United States. Their research spans multiple areas within medicine and biochemistry, genetics, and molecular biology. The scientist has contributed to fields such as molecular biology, oncology, pulmonary and respiratory medicine, cancer research, and neurology.

Their work covers key topics including:

  • Sarcoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Neuroblastoma Research and Treatments
  • Cancer-related molecular mechanisms research
  • Cancer, Hypoxia, and Metabolism
  • Cancer Genomics and Diagnostics
  • Protein Degradation and Inhibitors

Among recent publications, notable papers include:

  • The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models, 2021, Clinical Cancer Research
  • Predicting and characterizing a cancer dependency map of tumors with deep learning, 2021, Science Advances
  • Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma, 2022, npj Precision Oncology
  • Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma, 2021, Nature Communications
  • Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease, 2020, Oncotarget

The scientist frequently publishes in these venues:

  • Cancer Research
  • Pediatric Blood & Cancer
  • Cell Reports
  • Molecular Cancer Therapeutics
  • Clinical Cancer Research

Peter J. Houghton collaborates regularly with several researchers, including:

  • Raushan T. Kurmasheva
  • Malcolm A. Smith
  • Stephen W. Erickson
  • Richard Görlick
  • Yidong Chen

Best Publications

  • The tor pathway: a target for cancer therapy

    Mary-Ann Bjornsti;Peter J. Houghton

  • Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

    Gregory J. Brunn;Christine C. Hudson;Aleksandar Sekulić;Aleksandar Sekulić;Aleksandar Sekulić;Josie M. Williams

  • mTOR and cancer therapy.

    J B Easton;P J Houghton

  • Targeting mTOR signaling for cancer therapy.

    Shile Huang;Peter J Houghton

  • Establishment of human tumor xenografts in immunodeficient mice.

    Christopher L Morton;Peter J Houghton

  • The pediatric preclinical testing program: description of models and early testing results.

    Peter J. Houghton;Christopher L. Morton;Chandra Tucker;Debbie Payne

  • Methods to Detect P-Glycoprotein-associated Multidrug Resistance in Patients' Tumors: Consensus Recommendations

    William T. Beck;Thomas M. Grogan;Cheryl L. Willman;Carlos Cordon-Cardo

  • A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

    Sajid Khan;Xuan Zhang;Dongwen Lv;Qi Zhang

  • Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

    Peter J. Houghton;Pamela J. Cheshire;James D. Hallman;Lois Lutz

  • Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

    Peter J. Houghton;Glen S. Germain;Franklin C. Harwood;John D. Schuetz

  • Rapamycins: mechanism of action and cellular resistance.

    Shile Huang;Mary Ann Bjornsti;Peter J. Houghton

  • Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma

    Henry S. Friedman;William P. Petros;Allan H. Friedman;Larry J. Schaaf

  • Rapamycin Causes Poorly Reversible Inhibition of mTOR and Induces p53-independent Apoptosis in Human Rhabdomyosarcoma Cells

    Hajime Hosoi;Michael B. Dilling;Takuma Shikata;Linda N. Liu

  • A specific chromosomal abnormality in rhabdomyosarcoma

    Edwin C. Douglass;M. Valentine;E. Etcubanas;D. Parham

  • mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α

    Hakan Cam;John B. Easton;Anthony High;Peter J. Houghton;Peter J. Houghton

  • Potentiation of neuroblastoma metastasis by loss of caspase-8.

    Dwayne G. Stupack;Tal Teitz;Matthew D. Potter;David Mikolon

  • Biochemical Correlates of mTOR Inhibition by the Rapamycin Ester CCI-779 and Tumor Growth Inhibition

    Lorina Dudkin;Michael B. Dilling;Pamela J. Cheshire;Franklin C. Harwood

  • Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.

    Osama M. El-Badry;Caterina Minniti;Elise C. Kohn;Peter J. Houghton

  • Amplification of the gli Gene in Childhood Sarcomas

    Roberts Wm;Douglass Ec;Peiper Sc;Houghton Pj

  • Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.

    J.K. Peterson;P.J. Houghton

Frequent Co-Authors

Malcolm A. Smith
Malcolm A. Smith National Institutes of Health
Richard Gorlick
Richard Gorlick The University of Texas MD Anderson Cancer Center
John M. Maris
John M. Maris Children's Hospital of Philadelphia
C. Patrick Reynolds
C. Patrick Reynolds Texas Tech University Health Sciences Center
Janet A. Houghton
Janet A. Houghton Cleveland Clinic
Clinton F. Stewart
Clinton F. Stewart St. Jude Children's Research Hospital
Henry S. Friedman
Henry S. Friedman Duke University
John Easton
John Easton St. Jude Children's Research Hospital
Cheryl A. London
Cheryl A. London Tufts University
Shile Huang
Shile Huang Louisiana State University Health Sciences Center Shreveport

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, a variety of online degree options can help you start or advance your career in healthcare. For those interested in managing patient data and operational systems, an online MHI (Master of Health Information) provides an affordable route to enter health information management.

Students looking for specialized, technical roles may also consider medical billing and coding certification online. These programs offer career-focused training essential for working with insurance companies, hospitals, and clinics—skills highly sought-after in the healthcare industry.

Aspiring nurses can pursue their passion through nurse practitioner programs, which prepare graduates for advanced clinical roles. For those seeking a more affordable path, a cheapest online nursing program can lower the financial barrier to entry while providing a solid foundation for patient care careers.

Exploring these online pathways enables greater flexibility, practical skills, and numerous routes into the wider field of medicine—tailoring your studies to your interests, goals, and budget.

Best Scientists Citing Peter J. Houghton

Trending Scientists

Recently Published Articles